União Europeia - inglês - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - imipenem monohydrate, cilastatin sodium, relebactam monohydrate - gram-negative bacterial infections - carbapenems, antibacterials for systemic use, - recarbrio is indicated for:- treatment of hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap), in adults (see sections 4.4 and 5.1).- treatment of bacteraemia that occurs in association with, or is suspected to be associated with hap or vap, in adults.- treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options (see sections 4.2, 4.4, and 5.1).consideration should be given to official guidance on the appropriate use of antibacterial agents.

Malásia - inglês - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

fresenius kabi malaysia sdn. bhd - cilastatin sodium; imipenem monohydrate -

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

medreg s.r.o. - imipenem anhydrous cilastatin - pdr for soln for infusion - 500/500 milligram

Malásia - inglês - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

hovid berhad - imipenem monohydrate; cilastatin sodium -

Malásia - inglês - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

averroes pharmaceuticals sdn. bhd. - imipenem monohydrate; cilastatin sodium -

Cingapura - inglês - HSA (Health Sciences Authority)

alliance pharm pte. ltd. - imipenem monohydrate 530mg corresponding to imipenem; sodium cilastatin 530mg corresponding to cilastatin - injection, powder, for solution - 500mg - imipenem monohydrate 530mg corresponding to imipenem 500mg; sodium cilastatin 530mg corresponding to cilastatin 500mg

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - imipenem, quantity: 500 mg; cilastatin, quantity: 500 mg - injection, powder for - excipient ingredients: sodium bicarbonate - primaxin is indicated for the treatment of serious infections caused by susceptible strains of micro-organisms in the diseases listed below: 1. lower respiratory tract infections. 2 intra-abdominal infections. 3. gynaecological infections. 4. bacterial septicaemia. 5. bone and joint infections. 6. skin and skin structure infections. 7. endocarditis. 8. polymicrobial infections. primaxin is indicated for polymicrobial infections including those in which s. pneumoniae (pneumonia, septicaemia), group a beta-haemolytic streptococcus (skin and skin structure), or non-penicillinase-producing s. aureus is one of the causative organisms. however monobacterial infections due to these organisms are usually treated with narrower spectrum antibiotics, such as penicillin g. efficacy against polymicrobial infection in the immunocompromised host has not yet been established. although clinical improvement has been observed in patients with cystic fibrosis, chronic pulmonary disease, and lower respiratory tract infections cau

Cingapura - inglês - HSA (Health Sciences Authority)

novem pharma private limited - imipenem monohydrate 530mg corresponding to imipenem; sodium cilastatin 530mg corresponding to cilastatin - injection, powder, for solution - 500mg - imipenem monohydrate 530mg corresponding to imipenem 500mg; sodium cilastatin 530mg corresponding to cilastatin 500mg

Filipinas - inglês - FDA (Food And Drug Administration)

viridis enterprises - imipenem , cilastatin sodium - powder for injection im/iv - 500mg + 500mg

Cingapura - inglês - HSA (Health Sciences Authority)

fresenius kabi (singapore) pte ltd - imipenem monohydrate 530mg/vial eqv imipenem; sodium cilastatin 530mg/vial eqv cilastatin - injection, powder, for solution - imipenem monohydrate 530mg/vial eqv imipenem 500mg/ vial; sodium cilastatin 530mg/vial eqv cilastatin 500mg/ vial